OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial results for the quarter ended September 30, 2013, as well as recent highlights.
“We have continued to develop our EggPCSM technology platform and move forward with our planned international commercial activities for our first product candidate, AUGMENTSM,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience.
Help employers find you! Check out all the jobs and post your resume.
